Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml

Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +5% (cc¹, +6% USD)Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zol…

Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine

At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, SloveniaNew agreement follows earlier supply agreement for the fill …

Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz co…

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

Company previously disclosed settlement agreement in principle and fully provisioned for this resolutionBasel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Departme…

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine

Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further e…

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Ad hoc announcement pursuant to Art. 53 LRNet sales in Q2 grew +9% (cc¹, +14% USD):Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21% cc) and Zolgensma (+48% cc). Kesimpta sales reached USD …

Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia

Patients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable priceIron deficiency anemia occurs when there is a lower than normal number of oxygen-carrying red blood cells be…

Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer

Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1New ready-to-dilute format and 1,000 mg strength option helps avoid unnecessary handling steps to reduce asso…

Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe

Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls,…

US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case

Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wai…